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Background: Nitric oxide (NO) has numerous functions in the kidney, including control of renal and glomerular
hemodynamics, by interfering at multiple pathological and physiologically critical steps of nephron function.
Endothelial NOS (eNOS) gene has been considered a potential candidate gene to diabetic nephropathy (DN)
susceptibility. Endothelial nitric oxide synthase gene (eNOS-3) polymorphisms have been associated with DN, however
some studies do not confirm this association. The analyzed polymorphisms were 4b/4a, T-786C, and G986T.
Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement was used in this
report. Case–control studies that had diabetic patients with DN as cases and diabetic patients without nephropathy as
controls, as well as that evaluated at least one of the three polymorphisms of interest were considered eligible. All
studies published up until December 31st, 2012 were identified by searching electronic databases. Hardy-Weinberg
equilibrium assessment was performed. Gene-disease association was measured using odds ratio estimation based
on the following genetic contrast/models: (1) allele contrast; (2) additive model; (3) recessive model; (4) dominant
model and (4) co-dominant model.
Results: Twenty-two studies were eligible for meta-analysis (4b/a: 15 studies, T-786C: 5 studies, and G984T:
12 studies). Considering 4b/a polymorphism, an association with DN was observed for all genetic models: allele
contrast (OR = 1.14, CI: 1.04-1.25); additive (OR = 1.77, CI: 1.37-2.28); recessive (OR = 1.77, CI: 1.38-2,27); dominant
(OR = 1.12, CI: 1.01-1.24), with the exception for co-dominance model. As well, T-786C polymorphism showed
association with all models, with exception for co-dominance model: allele contrast (OR = 1.22, CI: 1.07-1.39),
additive (OR = 1.52, CI: 1.18-1.97), recessive (OR = 1.50, CI: 1.16-1.93), and dominant (OR = 1.11, CI: 1.01-1.23). For
the G894T polymorphism, an association with DN was observed in allelic contrast (OR = 1.12, CI: 1.03-1.25) and
co-dominance models (OR = 1.13, CI: 1.04-1.37).
Conclusions: In the present study, there was association of DN with eNOS 4b/a and T-786C polymorphism, which
held in all genetic models tested, except for co-dominance model. G894T polymorphism was associated with DN
only in allele contrast and in co-dominance model. This data suggested that the eNOS gene could play a role in
the development of DN.* Correspondence: brunodellamea@gmail.com
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Nitric oxide (NO) is a short-lived gaseous lipophilic mol-
ecule produced in almost all tissues and organs [1,2]. It is a
free radical that exerts a variety of biological actions under
both physiological and pathological conditions [3]. NO
is formed from its precursor L-arginine by a family of NO
synthases (NOSs). NOS system consists of three distinct
isoforms, encoded by three distinct genes, including neur-
onal (nNOS or NOS-1), inducible (iNOS or NOS-2), and
endothelial (eNOS or NOS-3). The gene encoding eNOS
is located on chromosome 7 (7q35-q36) and contains 26
exons, with an entire length of 21 kb [3,4].
NO has numerous functions in the kidney, including
control of renal and glomerular hemodynamics, by inter-
fering at multiple pathological and physiologically critical
steps of nephron function. NO dilates both the afferent
and the efferent arteriole, augmenting the glomerular
filtration rate (GFR) and influencing renal sodium handling
[5]. NO also mediates pressure natriuresis, maintenance
of medullary perfusion, decrease of tubuloglomerular
reabsorption, and modulation of renal sympathetic nerve
activity [6]. The net effect of NO in the kidney is to pro-
mote natriuresis and diuresis, along with renal adaptation
to dietary salt intake [7,8].
eNOS gene has been considered a potential candidate
gene to diabetic nephropathy (DN) susceptibility. Since
1998, several polymorphisms of the eNOS gene have been
identified, and their association with various diseases has
been explored. Three polymorphisms have been the sub-
ject of research in relation to DN, however the results are
highly variable. The polymorphisms potentially associated
with DN are a 27-bp repeat in intron 4 (VNTR), the
T-786C single nucleotide polymorphism (SNP) in the
promoter region (rs2070744), and G894T missense mutation
in exon 7 (rs1799983) [9]. Some of these polymorphisms
are associated with reduction of either eNOS activity
(−786C in the promoter area) or plasma concentrations
of NO (four repeats in intron 4) [2].
However, the potential association of eNOS gene vari-
ants with the induction and progression of DN remains
controversial. Some authors found a higher frequency of
eNOS polymorphisms in patients with end-stage renal
disease (ESRD) and DN [10-17], but not all studies reported
this association [18-20].
The objective of the present study was to evaluate if eNOS
gene polymorphisms are associated with DN through a
systematic review of the literature and a meta-analysis.
Results and discussion
Three-hundred and nine studies were identified, and 281
were excluded based on review of titles and abstracts
(70 animal experimental studies, 17 pharmacological stud-
ies, 86 without adequate cases or controls, 58 without
the genes or polymorphisms of interest, 3 review articles,5 meta-analysis, 35 studies with multiple publications
of the same data presented with different titles, 7 no
accesses to original data even after contacting authors).
Twenty-eight articles were eligible and had the full text
evaluated. Six studies were excluded due to lack of informa-
tion regarding genotypic distribution. A total of 22 studies
fulfilled the eligible criteria and were included for the
meta-analysis (Figure 1).
Clinical characteristics of individual studies are described
in Table 1. Regarding quality assessment, the phenotype
definitions as cases or controls were appropriated, but none
of the studies included information if genotyping was
performed by personnel blinded to clinical status. Of
the 22 studies included, 15 provided 4054/3405 cases/
controls for 4b/a; 5 provided 1436/1286 cases/controls
for T-786C; and 12 provided 3316/2765 cases/controls
for G894T. The allelic frequency of 4b, T-786, and G894 in
cases/controls was 6647/5702, 1863/1795, and 4691/4017
respectively (Table 2).
Hardy-Weinberg equilibrium (HWE) was assessed using
exact test and P-value < 0.05 were considered significant.
Only 4 studies (1 study for T-786C; 2 for G984T; and 1
for 4b/a) with controls were not in HWE (Table 2). These
studies were subjected to a sensitive analysis, and their
exclusion did not show significant difference on OR.
For the 4b/a polymorphism, an association with DN in
all genetic models, except for co-dominance, was obser-
ved: allele contrast (OR = 1.15, CI (95%): 1.05-1.25,
PQ <0.01, I
2 = 66%); additive (OR = 1.52, CI (95%): 1.18-
1.97, PQ <0.01, I
2 = 62%); recessive (OR = 1.50, CI
(95%): 1.16-1.93, PQ <0.01, I
2 = 64%); and dominant
(OR = 1.11, CI (95%): 1.01-1.23, PQ = 0.01, I
2 = 49%).
Similarly, for the T-786C polymorphism the association
with DN was found with all models, with exception for
co-dominance model: allele contrast (OR = 1.22, CI (95%):
1.07-1.39, PQ = 0.59, I
2 = 0%), additive (OR = 1.52, CI (95%):
1.18-1.97, PQ < 0.01, I
2 = 62%), recessive (OR = 1.50, CI
(95%): 1.16-1.93, PQ <0.01, I
2 = 64%) and dominant (OR =
1.11, CI (95%): 1.01-1.23, PQ <0.01, I
2 = 49%). The G894T
polymorphism showed association with DN in allelic con-
trast (OR = 1.12, CI (95%): 1.03-1.25, PQ <0.01, I
2 = 75%)
and co-dominance model (OR = 1.13, CI (95%): 1.04-1.37,
PQ = 0.01, I
2 = 60%) (Table 3 and Figure 2). A random model
analysis was performed confirming the fixed model results.
Publication bias was observed for the majority of the
polymorphisms evaluated and are presented as a funnel
plot for 4b/a polymorphsism (Figure 3). In order to identify
non published data, we performed manual search for ab-
stracts in some of the major scientific meetings in the field
in the last seven years. We estimated the effect of these po-
tential publication biases using trim and fill method and no
major differences were observed from the original results.
Since some studies included only subjects of specific
ethnicities or with type 1 or type 2 DM, we performed a
Literature search
Databases: PubMed, LILACS,
EMBASE and Cochrane Library
Meeting Abstracts: American
Diabetes Association, European




Article selection based on title 
and abstract
Included (n=28)









Review article / Meta-Analysis (n=8)
No access to original paper (n=7)
Excluded (n=6)
Data not shown (n=6)
Figure 1 Search strategy.
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characteristics. Considering 4b/a polymorphism, there was
an association in White and East Asian populations in allele
contrast, additive and recessive models; only for Whites in
the dominant model; and none for the co-dominant model.
For T-786C variant, no association was shown for Whites
in allele contrast analysis or in any other genetic model, but
in African populations the polymorphism was associated
with DN in allele contrast, dominance and co-dominance
models. Considering G894T polymorphism, in African
populations the association was observed for all genetic
models, with the exception of co-dominance model. There
were insufficient studies to perform a meta-analysis for
G894T in South Asians and West Asians.
According to the type of diabetes mellitus (DM), for 4b/a
polymorphism an association was observed in additive
and recessive models for both type 1 and type 2 diabetes,
and only for type 1 in allele contrast and dominant
models. There was no association with any type of DM in
co-dominant model for 4b/a variant. For T-786C, no asso-
ciation in any genetic model was found in type 2 diabetes.
There was insufficient data for this analysis in type 1 DM.Likewise, for G894T variant there was an association only
in the allele contrast model with type 2 diabetes (Table 3).
We compared the ORs of our meta-analysis with the re-
sults from a previous meta-analysis that used non-diabetic
patients as controls [30]. The results were similar and no
statistical differences in the ORs of the two studies were
observed in all genetic models analyzed (data not shown).
Conclusions
In the present study, the most robust association of DN
was with eNOS 4b/a and T-786C polymorphism that held
in all genetic models tested, except for co-dominance
model. G894T polymorphism was associated with DN
only in allele contrast and in co-dominance model. 4b/
a polymorphism association with DN was confirmed in
all ethnic groups evaluated and for all types of diabetes.
The subgroup analysis of the T-786C variant should be
viewed with caution, since it was limited due to the
small number of studies.
Analyzing genetic model is important, considering the
difference between them. Each individual genotype is
formed by two alleles (for example G and T for G984T
Table 1 Baseline studies characteristics
Author Year Polymorphism Type
of DM
Ethnicity Cases/controls (n) Criteria Male/female (%) Age DM duration
(years)
Ahluwalia et al. [21] 2008 G894T, 4a/b, T-786C 2 East Asians Case (195) Overt proteinuria 35/65 60.0 ± 6.15 16.5 ± 6.3
Control (255) Normoalbuminuria 41/59 60.5 ± 5.7 15.6 ± 5.2
Bessa et al. [22] 2011 G894T 2 African Case (40) Albuminuria > 30 mg/24 h 21/19 58.8 ± 12.5 19.4 ± 4.2
Control (40) Albuminuria < 30 mg/24 h 17/23 55.4 ± 8.8 15.3 ± 3.7
Cai et al. [23] 1998 G894T 2 Whites Case (116) Microalbuminuria NA NA NA
Control (284) Normoalbuminuria NA NA NA
Degen et al. [24] 2001 4a/b 1and 2 Whites Case (207) AER >30 mg/24 h NA NA >10 yrs
Control (418) AER <30 mg/24 h NA NA >10 yrs
Ezzidi et al. [10] 2008 G894T, 4a/b, T-786C 2 African Case (515) AER >30 mg/24 h 46/54 59.6 ± 10.8 13.5 ± 6.3
Control (402) AER <30 mg/24 h 42/58 59.1 ± 11.2 11.5 ± 6.2
Fujita et al. [25] 2000 4a/b 2 East Asians Case (102) AER >200 mcg/min 60/40 61.0 ± 21.0 NA
Control (65) AER <20 mcg/min 46/54 62.0 ± 10.0 NA
Ksiasek et al. [13] 2003 4a/b 2 Whites Case (178) With DN 48/52 57.9 ± 8.2 8.7 ± 3.1
Control (232) Without DN 51/49 58.3 ± 6.8 8.0 ± 2.6
Lin et al. [25] 2002 4a/b 2 East Asians Case (80) With DN NA NA NA
Control (48) Normoalbuminuria NA NA NA
Mollsten et al. [26] 2006 G894T, 4a/b 1 Whites Case (955) AER >20 mcg/min 58/42 40.3 ± 10.0 28 (5–65)
Control (555) AER <20 mcg/min + DM duration >20 yrs 41/59 42.2 ± 10.2 28 (20–57)
Mollsten et al. [18] 2009 G894T 1 Whites Case (458) AER >300 mg/24 h 39/61 42.0 ± 10.4 27 (7–65)
Control (319) AER <30 mg/24 h 55/45 43.7 ± 11.0 23 (15–63)
Neuguebauer et al. [14] 2000 4a/b 2 East Asians Case 1 (104) AER 20–200 mg/g Cr 53/47 59.0 ± 11.1 13.8 ± 5.1
Case 2 (39) AER >200 mg/g Cr 74/26 59.0 ± 8.6 15.2 ± 4.5
Control (82) AER <20 mg/g Cr 65/35 56.0 ± 8.6 13.3 ± 4.5
Rahimi et al. [27] 2012 G894T 2 West Asians Case 1 (68) Albumin to creatinin ratio >300 mg/g 33/35 57.1 ± 8.7 11.1 ± 6.4
Case 2 (72) Albumin to creatinin ratio 30–299 mg/g 23/46 55.3 ± 8.6 8.6 ± 5.2
Control (72) Albumin to creatinin ratio <30 mg/g 23/49 54.4 ± 7.9 7.7 ± 5.4
Rippin et al. [28] 2003 4a/b 1 Whites Case (464) Overt proteinuria NA NA NA
Control (396) Normoalbuminuria NA NA NA
Santos et al. [29] 2009 G894T, 4a/b, T-786C 2 Whites Case (376) AER >20 mcg/min or >17 mg/dl 57/43 60.4 ± 9.7 15.0 ± 9.1
Control (268) AER <20 mcg/min or <17 mg/dl 37/63 62.0 ± 9.4 16.7 ± 6.8
Shestakova et al. [16] 2006 4a/b 1 Whites Case (63) AER >300 mg/24 h 47/53 25.7 ± 6.4 12.6 ± 2.8





















Table 1 Baseline studies characteristics (Continued)
Shimizu et al. [30] 2002 4a/b 2 East Asian Case 1 (107) Overt proteinuria 70/30 63.1 ± 10.6 15.5 ± 11.0
Case 2 (124) Overt proteinuria + Cr >1.5 mg/dl 75/25 65.1 ± 8.8 19.8 ± 7.8
Control (203) Normoalbuminuria > DM >10 yrs 65/35 63.7 ± 8.8 18.6 ± 7.8
Shin Shin et al. [31] 2004 G894T 2 East Asians Case 1 (35) Microalbuminuria 46/54 62.9 ± 10.9 16 (12–20)
Case 2 (83) Overt proteinuria 46/54 58.8 ± 9.7 16 (11–20)
Control (59) Normoalbuminuric 25/75 61.6 ± 11.7 12 (10–16)
Shoukry et al. [32] 2012 G894T, 4a/b, T-786C 2 African Case Albumin to creatinin ratio >300 mg/g 108/92 55.3 ± 5.8 14.5 ± 4.3
Control Albumin to creatinin ratio <30 mg/g 116/84 54.6 ± 5.2 13.8 ± 3.2
Tamemoto et al. [33] 2008 G894T NA East Asians Case (124) Microalbuminuria NA NA NA
Control (211) Normoalbuminuria NA NA NA
Taniwaki et al. [20] 2001 4a/b 2 East Asians Case 1 (44) Microalbuminuria 59/41 60.5 ± 8.5 10.9 ± 7.4
Case 2 (22) Overt proteinuria 68/32 59.0 ± 10.5 12.8 ± 6.5
Case 3 (20) Overt proteinuria + Cr >1.5 mg/dl 50/50 64.2 ± 7.8 19.1 ± 9.7
Control (69) Normoalbuminuria 59/41 60.1 ± 9.8 7.4 ± 4.5
Tiwari et al. [19] 2009 G894T 2 South Asians Case 1 (90) DM >2 yrs + Cr >2 mg/dl from N India 87/13 53.6 ± 11.0 9.6 ± 6.8
Case 2 (106) DM >2 yrs + Cr >2 mg/dl from S India 76/24 55.9 ± 11.5 14.0 ± 6.4
Control 1 (75) DM >10 yrs + Cr <2 mg/dl from N India 53/47 61.0 ± 8.9 15.4 ± 8.1
Control 2 (149) DM >10 yrs + Cr <2 mg/dl from S India 68/32 60.5 ± 11.4 15.5 ± 6.91
Zanchi et al. [17] 2000 4a/b, T-786C 1 Whites Case 1 (74) AER >200 mcg/mg 42/58 35.5 ± 7.3 24.9 ± 9.0
Case 2 (78) AER >200 mcg/mg + Cr >1.5 mg/dl 49/51 35.7 ± 6.5 24.5 ± 6.8
Control (195) AER <20 mcg/mg + DM >15 yrs 52/48 36.5 ± 7.6 23.7 ± 6.3





















Table 2 Polymorphisms distribution
Author Distribution of the T-786C polymorphism HWE
Cases Controls p value
TT TC CC TT TC CC
Ahluwalia et al. [21] 121 62 12 165 87 3 0.020
Ezzidi et al. [10] 261 215 34 224 139 32 0.115
Santos et al. 2011 [29] 140 160 76 93 104 44 0.138
Shoukry et al. 2012 [32] 57 89 54 84 83 33 0.129
Zanchi et al. [17] 57 65 30 75 100 20 0.123
Distribution of the G894T polymorphism HWE
Cases Controls p value
GG GT TT GG GT TT
Ahluwalia et al. [21] 82 81 32 125 105 25 0.658
Bessa et al. 2011 [22] 10 18 12 17 19 4 1.000
Cai et al. [23] 65 44 7 148 109 27 0.310
Ezzidi et al. [10] 185 247 81 165 195 41 0.151
Mollsten et al. [34] 492 365 89 268 232 51 0.919
Mollsten et al. [18] 293 133 32 182 121 16 0.540
Rahimi et al. 2012 [27] 68 45 13 39 17 7 0.038
Santos et al. 2011 [29] 176 166 32 118 95 22 0.640
Shin Shin et al. [31] 95 23 0 52 7 0 1.000
Shoukry et al. 2012 [32] 66 94 40 99 77 24 0.140
Tamemoto et al. [33] 104 18 2 181 27 3 0.117
Tiwari et al. [19] 82 21 3 91 43 13 0.035
Distribution of the 4b/4a polymorphism HWE
Cases Controls p value
bb ba aa bb ba aa
Ahluwalia et al. [21] 146 28 21 189 61 5 1.000
Degen et al. [24] 229 94 4 297 105 9 1.000
Ezzidi et al. [10] 314 162 29 234 143 21 1.000
Fujita et al. [25] 81 21 0 55 10 0 1.000
Ksiasek et al. 2003 [13] 105 58 15 147 66 19 0.007
Lin et al. [26] 115 21 1 41 6 1 0.271
Mollsten et al. [34] 656 248 39 389 145 19 0.220
Neugebauer et al. [14] 101 26 6 71 10 1 0.351
Rippin et al. [28] 344 108 12 297 90 9 0.519
Santos et al. 2011 [29] 237 99 11 168 59 5 1.000
Shestakova et al. [16] 14 48 1 34 31 1 0.052
Shimizu et al. [30] 180 44 6 156 44 3 1.000
Shoukry et al. 2012 [32] 124 64 12 131 60 9 0.502
Taniwaki et al. [20] 63 21 2 50 19 0 0.340
Zanchi et al. [17] 80 27 37 144 47 4 1.000
HWE (Hardy-Weinberg equilibrium).
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on the number of variant allele copies carried, where
one of which is thought to be associated with a disease(e.g., T), association studies will collect information on
the numbers of diseased and disease-free subjects with
each of the three genotypes (GG, GT, and TT). So we
Table 3 Meta-analysis in all genetic models with all patients and subgroup analysis, in fixed-model analysis, presenting
heterogeneity (PQ and I
2)
Population Studies OR IC (95%) P PQ I
2 (%)
4b/a
Allele contrast All 15 1.15 1.05-1,25 <0.01 <0.01 66
African 2 0,98 0.81-1.18 0.88 0,25 22
East Asians 6 1.21 0.97-1.50.8 0.08 0.29 18
Whites 7 1.20 1.07-1.34 <0.01 <0.01 80
Type 1 5 1.17 1.02-1.34 0.02 0.07 54
Type 2 10 1.12 0.99-1.27 0.07 0.28 18
Additive All 15 1.52 1.18-1.97 <0.01 <0.01 62
African 2 1,13 0,69-1,81 0.62 0.56 0
East Asians 6 3.25 1.58-6.68 <0.01 0.31 16
Whites 7 1.49 1.06-2.08 0.01 <0.01 74
Type 1 5 2.21 1.50-3.25 <0.01 <0.01 81
Type 2 11 1.36 0.98-1.88 0.06 0.08 41
Recessive All 15 1.50 1.16-1.93 <0.01 <0.01 64
Africans 2 1.13 0.69-1.83 0,61 0.83 0
East Asians 6 3.44 1.68-7.05 <0.01 0.28 21
Whites 7 1.43 1.03-1.99 0.03 <0.01 75
Type 1 5 2.19 1.49-3.21 <0.01 <0.01 81
Type 2 11 1.49 1.07-2.07 0.02 0.08 42
Dominant All 15 1.11 1.01-1.23 0.03 0,01 49
African 2 0.94 0.75-1.18 0.64 0.24 27
East Asians 6 1.04 0.81-1.34 0.71 0.44 0
Whites 7 1.20 1.05-1.36 <0.01 <0.01 67
Type 1 5 1.22 1.04-1.43 0.01 <0.01 78
Type 2 11 1.05 0.92-1.20 0.44 0.62 0
Codominant All 15 0.98 0.88-1.09 0.81 0,02 46
African 2 1.09 0.87-1.38 0.42 0.29 7
East Asians 6 1.17 0.90-1.55 0.22 0.14 38
Whites 7 0.90 0.79-1.04 0.16 0.04 54
Type 1 5 0.94 0.80-1.11 0.46 0.01 68
Type 2 11 1.01 0.88-1.17 0.80 0.19 26
T-786C
Allele contrast All 5 1.28 1.14-1.44 <0.01 0.25 24
African 2 1.44 1.21-1.71 <0.01 0.26 19
Whites 2 1.13 0.94-1.36 0.19 0.44 0
Type 2 4 1.29 1.13-1.46 <0.01 0.15 42
Additive All 5 1.48 1.14-1.92 <0,01 0.01 67
African 2 1.43 0.98-2.09 0.05 0.01 84
Whites 2 1.36 0.93-1.98 0.10 0.18 42
Type 2 4 1.40 1.06-1.86 0.01 <0.01 73
Recessive All 5 1.38 1,09-1.76 <0,01 0.01 68
African 2 1.24 0.88-1.76 0.21 0.01 81
Whites 2 1.39 0.98-1.95 0.06 0.09 0
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Table 3 Meta-analysis in all genetic models with all patients and subgroup analysis, in fixed-model analysis, presenting
heterogeneity (PQ and I
2) (Continued)
Type 2 4 1.27 0.98-1.65 0.06 0.01 72
Dominant All 5 1.21 1,04-1.42 0.01 0.29 18
African 2 1.39 1.11-1.73 <0.01 0.13 54
Whites 2 1.05 0.81-1.37 0.70 0.95 0
Type 2 4 1.24 1.05-1.47 <0.01 0.22 31
Codominant All 5 0.95 0.81-1.11 0.53 0.12 45
African 2 0.78 0.62-0.98 0.03 0.48 0
Whites 2 1.15 0.89-1.49 0.28 0.24 25
Type 2 3 0.90 0.75-1.06 0.20 0.131 15
G986T
Allele contrast All 12 1.12 1.03-1.21 <0.01 <0.01 75
African 3 1.63 1.39-1.91 <0.01 0.61 0
East Asian 3 1.33 1.05-1.70 0.01 0.74 0
Whites 4 0.93 0.84-1.04 0.20 0.67 0
Type 1 2 0.92 0.80-1.04 0.18 0.18 0
Type 2 9 1.27 1.15-1.42 <0.01 <0.01 72
Additive All 12 1.19 0.99-1.43 0.05 <0.01 63
African 3 2.01 1.50-2.94 <0.01 0.27 22
East Asian 3 1.85 1,05-3.25 0.03 0.59 0
Whites 4 0.86 0.67-1.10 0.23 0.69 0
Type 1 2 0.87 0.65-1.16 0.34 0.44 0
Type 2 9 1.47 1.16-1.86 <0.01 <0.01 63
Recessive All 12 1.16 0.97-1.38 0.09 0.02 52
Africa 3 1.80 1.31-2.46 <0.01 0.43 0
East Asian 3 1.73 1.01-2.96 0.04 0.63 0
Whites 4 0.88 0.69-1.11 0.29 0.62 0
Type 1 2 0.91 0.69-1.20 0.49 0.31 0
Type 2 9 1.36 1.08-1.70 <0.01 0.03 53
Dominant All 12 0.99 0.89-1.11 0.92 0.07 45
African 3 1.46 1.17-1.82 <0.01 0.11 54
East Asian 3 1.32 0.98-1.79 0.06 0.73 0
Whites 4 0.93 0.80-1.07 0.31 0.59 0
Type 1 2 0.89 0.75-1.06 0.19 0.74 0
Type 2 9 1.19 0.92-1.26 0.35 0.04 57
Codominant All 12 1.03 1.04-1.37 0.01 0.01 60
African 3 0.92 0.74-1.14 0.45 0.29 18
East Asian 3 0.89 0.65-1.21 0.48 0.52 0
Whites 4 1.02 0.89-1.18 0.69 0.44 0
Type 1 2 1.08 0.91-1.29 0.35 0.32 0
Type 2 9 0.94 0.82-1.08 0.41 0.34 11
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of alleles G with the number of alleles G; the additive
model, which contrasts extreme homozygotes, comparing
the genotype GG with the genotype TT; in recessivemodel two copies of T allele are essential to modify the
risk, combining the GG and GT genotypes and comparing
with TT; the dominant model, which heterozygous GT and
homozygous TT genotypes have the similar risk as a single
Figure 2 Forest plot for contrast allele model for (A) 4b/a polymorphism; (B) T-786C polymorphism; and (C) G894T polymorphism.
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http://www.biomedcentral.com/1471-2350/15/9copy of T is sufficient to alter the risk, then compares
GG with combined GT and TT genotypes; and the
codominance model, commonly used genetic model,where each genotype gives a diverse and non additive
risk. which combines the GG and TT genotypes and
compares with GT. So OR in each particular genetic
Figure 3 Funnel plot for 4b/a polymorphism: (A) allele contrast; (B) additive; (C) recessive; (D) dominant; (E), codominant.
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of the polymorphisms.
These results are original and help to understand the
role of these polymorphisms in the development of DN.
However, it was not possible to exclude a publication
bias of negative studies. Therefore, the exact effect could
be smaller. As discussed before, other explanations, besides
classic risk factors, are needed for understanding theprogression of a diabetic patient from normoalbuminuria
to macroalbuminuria, and a polymorphism identification
of a specific gene would propitiate the development of a
new therapy aimed directly to it.
In contrast to a recent meta-analysis performed by
Zintzaras et al. [30], which analyzed the same polymor-
phisms in the progression of DN, our analysis com-
pared diabetic patients with DN (cases) with diabetic
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subjects were used as controls, mixed with patients
with DN. When the controls are defined as non-diabetic
subjects, the observed association could reflect a genetic
predisposition for individuals to develop “diabetic ne-
phropathy”. The obtained results could reflect a mixture
of a susceptibility to diabetes per se and to nephropathy,
which cannot be discriminated. In this regard, to serve
non-diabetic individuals as controls seem rationale to
estimate a risk of diabetic nephropathy. However, from
clinical points of view, most of medical staff would be
interested in risks for nephropathy among individuals
with diabetes, as in the case with hyperglycemia, rather
than combined risks for developing diabetes and for ne-
phropathy thereafter. That is why diabetic individuals
showing no or little nephropathy despite a term of dur-
ation have been widely investigated as controls, in most
of the previous studies. So, our work and Zintzaras are
derived from different standing points: a clinical aspect
and a bio-mathematic research.
In this sense, we considered that the optimal control
group when studding a DM complication is a diabetic pa-
tient without the complication and with disease duration
long enough the permit a genetic predisposition to be-
come clinically detected in the presence of hyperglycemia.
Moreover, the disease duration must be comparable be-
tween cases and controls. Most included studies fulfilled
the two pre-requisitions. As can be seen in Table 1, the
DM duration is similar between cases and controls in each
study and the majority has more than 10 years of DM,
reflecting that authors from original studies probably took
this important issue in consideration.
Despite the different control used by Zintzaras, they
found 92 articles, being 20 included for meta-analysis; that
provided 1942/1461 cases/controls for G894T, 2663/2232;
cases/controls for 4b/a, and 857/845 cases/controls for
T-786C. That was similar to ours that had 22 studies
included, but provided about one third more cases/
controls. The OR observed in their analyzes showed signifi-
cance in allelic contrast model for G894 polymorphism,
recessive and additive model for 4b/a polymorphism, and
allelic contrast model for T-786C, all observed in our study;
but our analyze showed association in more genetic models
than that, like codominant model for G894T; allele contrast
and dominant model for 4b/a; recessive, dominant and
additive model for T786C. Furthermore, we compared
our ORs with those reported by Zintzaras et al. and no
statistical differences were found. With that said, our
study reinforce the findings from Zintzaras.
DN development predisposition has not been fully ex-
plained, since glycemic control and environmental factors,
as well as traditional risk factors, do not accurately predict
the occurrence of this diabetic complication in all patients.
With this in mind, studies have been trying to resolve thisquestion using genetic approaches. Many candidate genes
have been explored in this context, and eNOS polymor-
phisms have been implicated in the susceptibility to glom-
erular disease, by mechanisms yet unknown [15]. However,
there is no consensus on the role of these polymorphisms
in modulation of risk for DN, since the available literature
demonstrates mixed results and most of the studies have a
small sample. In this scenario, the recommended approach
to help investigators in understanding the effect of each
polymorphism in DN development is a systematic re-
view and meta-analysis. Our data suggest an association
between eNOS polymorphisms and DN. Assuming a reces-
sive model, the relative risk, attributable risk and population
attributable risk for the 4a variant ranges are, respectively,
1.20; 0.11; and 0.09.
The present paper has some limitations. The inclusion
of studies evaluating patients with DM in several stages
of DN, ranging from microalbuminuria to chronic renal
insufficiency in kidney replacement therapy, could bias
the results due to clinical heterogeneity of cases. Some
studies did not present the data separated by DN stages.
Furthermore, inclusion criteria in the reviewed studies
utilized different methods and cutoffs to define microal-
buminuria or macroalbuminuria. Although all clinically
validated [35], these aspects made impossible to evaluate
the effect of each polymorphism in the stages of DN in
this meta-analysis. Finally, the polymorphisms true effects
could be overestimated in the present study, since there is
some indication of publication bias.
In conclusion, this study shows an association between
DN and polymorphisms in eNOS gene. This effect is very
consistent for the 4b and T-786 polymorphism.
Methods
The Preferred Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) statement was used in this
report [36,37].
Selection criteria and search strategy
Case–control studies that had diabetic patients with DN
as cases and diabetic patients without nephropathy as
controls, as well as that evaluated at least one of the three
polymorphisms of interest (4b/4a, T-786C, G986T) were
considered eligible. Only studies in humans and using vali-
dated genotyping methods were considered. No publication
language, publication date, or publication status restrictions
were imposed. All studies published up until December
31st, 2012 were identified by searching electronic databases:
Medline (1966-Present), EMBASE (1980-Present), LILACS
and Cochrane Library.
Abstracts presented at scientific events held by: The
American Diabetes Association (ADA); The European
Association for the Study of Diabetes (EASD); The National
Kidney Association (NKA); and The American Society
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http://www.biomedcentral.com/1471-2350/15/9of Nephrology (ASN) were searched over the last seven
years. The authors were contacted for more details in
the case of abstracts with missing information.
The following index terms were used: (“Nitric Oxide
Synthase Type III” OR “NOS3 protein, human”) AND
(“Databases, Genetic” OR “Genetic Predisposition to
Disease” OR “Genetic Phenomena” OR “Genetic Processes”
OR “Genetic Markers” OR “Genetic Variation” OR
“Polymorphism, Genetic” OR “Genetic Research” OR
“Genetic Determinism” OR “Genes” OR “Genetics”
OR “Mutation” OR “Genetics, Medical” OR “DNA”) AND
(“Proteinuria” OR “Albuminuria” OR “Kidney Failure”
OR “Kidney Failure, Chronic” OR “Kidney Diseases”
OR “Diabetic Nephropathies”).
Study selection and data extraction
Eligibility assessment was made by title and abstracts
review and in doubtful cases by full article review. This
was performed independently in a standardized manner by
two investigators (BSD and CBL). Disagreements between
reviewers were resolved by consensus.
Two investigators extracted the data, one independent
to another (BSD and LCFP). Disagreements were resolved
by a third author (LHC). For articles with missing informa-
tion, (n = 3) the authors were contacted for further infor-
mation, but none responded. In the case of duplicate
publications, the first manuscript published was included in
the analysis. Information was extracted from each individ-
ual study based on: (1) characteristics of study participants
(including age, gender, type of diabetes, diabetes duration,
nephrologic status, and ethnicity) [38], (2) case and control
definition; (3) genetic data (including allelic distribution
and genotypic frequency).
Quality assessment
To ascertain the validity of each eligible case–control
study, two investigators (BSD and LCFP) worked inde-
pendently during the initial search and after worked to-
gether to determine the adequacy of studies selection. It
was assessed if the same exclusion criteria for cases and
controls were used; if cases were easily differentiated
from controls; if analysis of studied polymorphisms were
conducted in a standard, valid, and reliable way, if major
biases were identified and considered in design and ana-
lysis; and how good the study was to minimize the risks of
bias or confusion. Hardy-Weinberg equilibrium assessment
among the control group within each polymorphism in all
studies was checked by exact test using an online HWE
calculator (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl).
Statistical analysis
Gene-disease association was measured using odds ratio
estimation based on the following genetic contrast/models:
(1) allele contrast; (2) additive model; (3) recessive model;(4) dominant model and (4) co-dominant model [39,40].
Heterogeneity was tested by chi-squared test, Cochran’s Q,
and inconsistency with I2. If PQ <0.10, then heterogeneity
was considered statistically significant. Odds ratio was
calculated using fixed-effect models (Mantel-Haenszel), and
random models when heterogeneity was observed. Multiple
comparisons were not made because meta-analysis of gen-
etic association studies is considered an exploratory study,
without a prespecified key hypothesis [41,42].
The risk of publication bias was evaluated using funnel
plot graphics [43].
Sensibility tests were made concerning to ethnia and
type of diabetes.
Data were analyzed using Stata/SE 11.2 (http://www.
stata.com).
We compared the ORs of our meta-analysis with the
results from a previous one [44] that used non-diabetic
patients as controls using the differences of OR and 95%
CI (WinPepi version 11.3).
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